Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.
ReciBioPharm is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Headed by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.
Areterna Co., Ltd. is a company that provides materials and services to support mRNA and oligonucleotide manufacturing. Founded in 2018 by a group of passionate nucleic acid chemists, the goal of the company is to debottleneck the raw material supply and develop innovative solutions to support customers in the industry. The company has a robust quality system and ISO9001 certification to support cGMP manufacturing of mRNA raw materials that include NTPs, modified NTPs and cap analogs. For the GMP raw materials, Drug Master Files have been filed with FDA. In addition, Areterna offers analytical development service and mRNA-related impurity standards and detection kits, LNP screening service, IVT process development and IVT kits for mRNA research. For solid-phase DNA and RNA synthesis, Areterna offers high quality phosphonamidites to support cGMP oligo manufacturing. With over 200 people in R&D and AI-assisted discovery platform, Areterna will continue to bring new products to the market.
Ziccum's patented technology LaminarPace gently dries liquid biopharmaceuticals such as vaccines or protein therapeutics into a particle engineered powder product. For patient administration, the drug powder may be reconstituted, which means mixed with liquid and injected just like a liquid solution vaccine, or directly administered in powder form by inhalation or other novel administration routes. The gentle processing in ambient temperature enables thermostable powder biopharmaceuticals. This means that the biological drug or vaccine can be transported and stored at room temperature, unlike today's liquid biologics that require costly, complex logistics with an unbroken cold chain, or even freeze chain.
CATUG Biotechnology (Suzhou) Co., Ltd. was established in June 2021. With R&D centers and industrialization base settled in China, CATUG is an innovative technology company focusing on nucleic acid process development and application. Our aim is to build a leading One-stop CRDMO Service Platform for Cell and Gene Therapy & Nucleic Acid Therapy. Our first-rate plasmid and mRNA technology provide services for the entire industrial chain from product development, quality research, clinical application to industrialization and LNP encapsulation of cell therapy and nucleic acid drugs.
Based on 60 years of experience in the development and manufacturing of scientific instruments, KNAUER also offers custom engineering of equipment for the laboratory and for GMP production.
The company’s most recent development in this field – lipid nanoparticles (LNP) production systems – have enabled the large-scale manufacturing of mRNA-based vaccines to fight the Corona pandemic.
Traditionally, KNAUER is best known for its high-precision liquid chromatography systems (HPLC and FPLC) and related components. The systems are used to analyze samples for ingredients and impurities and determine their quantities, both in the laboratory and in process analysis. The systems can also purify value substances such as active pharmaceutical ingredients on a laboratory scale.
KNAUER’s valves, pumps, detectors, and other components are also used for tasks such as high-pressure dosing and various flow detection tasks in different applications. OEM manufacturing LC components for other suppliers is an important part of KNAUER’s business.
For nearly 30 years we have helped the world’s most innovative bio/pharmaceutical companies to navigate the challenges of new product development, drug delivery, production, and market release. We provide a broad range of cGMP, GLP, GCP laboratory services, with a focus on support for the development and production of mRNA, oligos, peptides, biologics, or vaccines. We are adept in establishing GMP validated analytical methods including mRNA specific methods such as integrity, potency, capping efficiency, sequencing, Poly(A) Tail, residual DNA template, residual dsRNA and delivery system testing (e.g. lipid nanoparticles (LNPs)). These comprehensive characterisation services provide data to determine protein expression and product purity, which can be directly linked to translation efficiency and immunogenicity. We also provide ICH stability and formulation development programs and have leading expertise in the product development of inhaled and nasal drugs.
Our outsourcing contracts are flexible and can be tailored to your specific timelines, requirements, and budgets.
We are a clinical trial and pipeline database solution designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving drug development landscape. For more information or to request a demo, visit our website.